23:45 , Jun 19, 2019 |  BC Extra  |  Clinical News

June 19 Clinical Quick Takes: G1 jumps on breast cancer data; plus Linzess, Lokelma, Boehringer/OSE, GCAR and more

G1 rises on trilaciclib OS efficacy in Phase II for TNBC  G1 Therapeutics Inc. (NASDAQ:GTHX) has gained 33% to $26.27 since reporting preliminary data Tuesday from a Phase II trial showing a statistically significant improvement...
20:52 , May 20, 2019 |  BC Innovations  |  Distillery Therapeutics

Cyclerion's sGC stimulator praliciguat ameliorates NASH in rodents

DISEASE CATEGORY: Hepatic INDICATION: Non-alcoholic steatohepatitis (NASH) Rat and mouse studies suggest the systemic sGC stimulator praliciguat could help treat NASH. In liver samples from patients, levels of an sGC subunit were higher in fibrotic...
20:26 , May 15, 2019 |  BC Extra  |  Financial News

May 15 Financial Quick Takes: Perceptive leads $60M round for ArcherDx; plus Applied Therapeutics’ IPO, IsoPlexis, Symphogen

ArcherDx completes $60M series B  New investor Perceptive Advisors led a $60 million series B round for ArcherDx Inc. (Boulder, Colo.) that the company plans to use to scale operations, advance its companion diagnostic program...
00:00 , May 14, 2019 |  BC Extra  |  Preclinical News

Cyclerion's sGC activation could work for NASH

With new preclinical data in hand, Ironwood-spinout Cyclerion is making the case for extending its lead sGC stimulator praliciguat into NASH. Cyclerion Therapeutics Inc. (NASDAQ:CYCN) completed its spinout from Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) in April...
00:05 , Apr 12, 2019 |  BC Week In Review  |  Financial News

Cyclerion launches, raises $175M private placement

Cyclerion completed its spinout from Ironwood on April 2 and raised $175 million in a private placement from members of Cyclerion management, including CEO Peter Hecht and President and CSO Mark Currie, and undisclosed existing...
20:38 , Apr 9, 2019 |  BC Extra  |  Company News

Management tracks: Cyclerion, Alkermes, Alder

A week after completing its spinout from Ironwood, Cyclerion has hired Andreas Busch as chief innovation officer. Busch was EVP, head of R&D and CSO at Shire plc and previously served as EVP, head of...
00:04 , Apr 6, 2019 |  BioCentury  |  Finance

Everybody up

Biotech stocks were off to a strong start in 1Q19, with 71% of companies tracked by BioCentury seeing market cap growth in the quarter. Across all market cap bands, biotechs saw a median gain of...
02:42 , Feb 28, 2019 |  BC Week In Review  |  Financial News

Ironwood spinout Cyclerion planning $175M private placement

Cyclerion Therapeutics Inc. (Cambridge, Mass.) plans to raise up to $175 million in a private placement when the company completes its planned spinout from Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) in early April. Ironwood said up to...
21:54 , Feb 26, 2019 |  BC Extra  |  Financial News

Ironwood spinout Cyclerion planning $175M private placement

Cyclerion Therapeutics Inc. (Cambridge, Mass.) plans to raise up to $175 million in a private placement when the company completes its planned spinout from Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) in early April. Ironwood said up to...
23:50 , Jan 28, 2019 |  BC Extra  |  Company News

Management tracks: Ironwood reveals board for new companies

Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) named Mark Currie as incoming president of its spinout Cyclerion Therapeutics Inc. Currie will also join Ironwood's board following the separation, which is on track to occur this half. He is...